Is a 2‐week regimen of tecovirimat sufficient for the treatment of Mpox (monkeypox) in advanced HIV patients with a low CD4 cell count?
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29617 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Joo-Hee Hwang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea. Hauptthemen laut MEDLINE: HIV Infections. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea.
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.
Zitieren
APA
Hwang, J. H., & Hwang, J. H. (2024). Is a 2‐week regimen of tecovirimat sufficient for the treatment of Mpox (monkeypox) in advanced HIV patients with a low CD4 cell count?. Journal of Medical Virology. https://doi.org/10.1002/jmv.29617
Vancouver
Hwang JH, Hwang JH. Is a 2‐week regimen of tecovirimat sufficient for the treatment of Mpox (monkeypox) in advanced HIV patients with a low CD4 cell count?. Journal of Medical Virology. 2024. doi:10.1002/jmv.29617
BibTeX
@article{Hwang2024,
author = {Hwang, Joo-Hee and Hwang, Jeong-Hwan},
title = {Is a 2‐week regimen of tecovirimat sufficient for the treatment of Mpox (monkeypox) in advanced HIV patients with a low CD4 cell count?},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29617}
}
EUVIMED